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Abstract
Background: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in infants. Following RSV
bronchiolitis, 50% of children develop post-bronchiolitis wheeze (PBW). Animal studies have suggested that
interleukin (IL)-10 plays a critical role in the pathogenesis of RSV bronchiolitis and subsequent airway
hyperresponsiveness. Previously, we showed that ex vivo monocyte IL-10 production is a predictor of PBW.
Additionally, heterozygosity of the single-nucleotide polymorphism (SNP) rs1800872 in the IL10 promoter region
was associated with protection against RSV bronchiolitis.
Methods: This study aimed to determine the in vivo role of IL-10 in RSV pathogenesis and recurrent wheeze in a
new cohort of 235 infants hospitalized for RSV bronchiolitis. IL-10 levels in nasopharyngeal aspirates (NPAs) were
measured at the time of hospitalization and the IL10 SNP rs1800872 genotype was determined. Follow-up data
were available for 185 children (79%).
Results: Local IL-10 levels during RSV infection turned out to be higher in infants that later developed physician
diagnosed PBW as compared to infants without PBW in the first year after RSV infection (958 vs 692 pg/ml, p =
0.02). The IL10 promoter SNP rs1800872 was not associated with IL-10 concentration in NPAs.
Conclusion: The relationship between high local IL-10 levels during the initial RSV infection and physician
diagnosed PBW provides further evidence of the importance of the IL-10 response during RSV bronchiolitis.
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Background
Respiratory syncytial virus (RSV) is a negative-sense, sin-
gle-stranded RNA virus and a member of the Paramyxo-
viridae, subfamily Pneumovirinae.R S Vc a u s e saw i d e
range of clinical symptoms, varying from mild upper
respiratory tract infection to severe bronchiolitis and
pneumonia [1,2]. It is the most common cause of severe
lower respiratory tract infection in children aged less
than 1 year, and approximately 1-3% require hospitaliza-
tion [3,4]. High-risk groups for severe RSV infection
include infants with preterm birth, chronic lung disease
of prematurity, congenital heart disease, cystic fibrosis,
immunodeficiency disorders, and Down’ss y n d r o m e
[5,6]. Besides infants, specific adult populations are also
at risk to develop severe RSV infection [7-10]. However,
most infants hospitalized for RSV infection are pre-
viously healthy infants and do not fit the profile of a
high risk patient [11]. RSV bronchiolitis is often fol-
lowed by recurrent episodes of wheeze, in about 50% of
cases, also referred to as post-bronchiolitis wheeze
(PBW) [12-16]. PBW causes significant healthcare costs,
and influences quality of life [17,18]. Since there is no
effective therapy or vaccine for RSV infection, it is cru-
cial for future management to characterize the precise
mechanisms of this complex infection, including the
development of PBW.
Identification of the functionality of genes that play an
important role in disease susceptibility could enhance
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opment. The immunoregulatory effect of cytokine inter-
leukin (IL)-10 on RSV infection has been widely
investigated both in animal models [19,20] and human
studies [21,22]. IL-10 is mainly produced by macro-
phages, monocytes, T cells, B cells, dendritic cells, mast
cells and eosinophils. IL-10 can downregulate cytokine
production by Th1-like T-cells and inhibit antigen
presentation through downregulation of class II major
histocompatibility complex antigens on monocytes
[23,24]. Overexpression of IL-10 in the nasal mucosa of
transgenic mice suppresses RSV replication in the
respiratory tract [25], while ovalbumin-sensitized and
challenged IL-10-/- mice develop airway hyperrespon-
siveness only if infected with RSV [26]. In RSV infected
children IL-10 is elevated in nasopharyngeal secretions
[27-29], while IL-10 is lower in atopic infants versus
patients without atopy [30]. IL-10 plasma concentrations
are higher in RSV infected hypoxic compared to non-
hypoxic infants [31]. Previously, we have shown that IL-
10 produced by monocytes of RSV infected infants is
implicated in the occurrence of PBW [32]. Nonetheless,
the relevance of IL-10 production in blood for the local
response in RSV infected lungs is unknown. For the cur-
rent study on the pathogenesis of PBW we have focused
on the single-nucleotide polymorphism (SNP)
rs1800872, which is located in the promoter region of
the IL10 gene and therefore affects IL-10 production at
the site of infection [33]. Heterozygosity of this SNP was
associated with increased resistance to severe RSV infec-
tion [34]. Twin and family studies have shown that
between 50% and 75% of the observed variability of IL-
10 secretion is explained by genetic factors [35-37]. To
clarify the role of IL-10 in the pathogenesis of PBW, the
association between IL-10 levels during RSV infection
and the IL10 promoter SNP rs1800872 with the devel-
opment of PBW was investigated.
Methods
Study populations
The RSV-NPA study is a multicenter cohort study with
previously healthy infants hospitalized with a first epi-
sode of RSV bronchiolitis before 13 months of age.
Infants with Down syndrome, a history of wheezing, or
cardiac or pulmonary pathology were excluded. Healthy
infants with preterm birth were included. In total, 235
infants were included from October 2007 until March
2009 in fifteen large urban hospitals in The Netherlands
(Flevo Hospital, Almere; Meander Medical Center,
Amersfoort; Gelre Hospital, Apeldoorn; Alysis Rijnstate
Hospital, Arnhem; Gelderse Vallei Hospital, Ede; Rivas
Beatrix Hospital, Gorinchem; Jeroen Bosch Hospital, ‘s-
Hertogenbosch; Tergooi Hospital, Blaricum; St. Anto-
nius Hospital, Nieuwegein; Twee Steden Hospital,
Tilburg; Diakonessen Hospital, Utrecht; Mesos Medical
Center, Utrecht; University Medical Center, Utrecht;
Maxima Medical Center, Veldhoven; Zuwe Hofpoort
Hospital, Woerden). RSV infection was confirmed by
positive immunofluorescence in epithelial cells from
nasopharyngeal aspirates (NPAs) using the routine diag-
nostic procedures in the participating hospitals. Due to
limited amount of NPA available for research, RSV
detection was not confirmed by another method like
PCR. All infants admitted to the pediatric intensive care
unit (PICU) were intubated and mechanically ventilated,
therefore stay at the PICU was identical to the require-
ment of mechanical ventilation. PBW was defined as a
minimum of one wheezing episode diagnosed by a phy-
sician in the first year after hospitalization for RSV
bronchiolitis. Follow-up data were available for 185 chil-
dren (79%). If a general practitioner repeatedly did not
respond to our questionnaire despite several attempts,
PBW was classified as unknown. All parents of hospita-
lized infants agreed to participate and gave written
informed consent. The study protocol was approved by
the institutional review boards of all participating
hospitals.
Controls (n = 1008) for genetic association were ran-
domly taken from the Regenboog study, a large Dutch
population health examination survey [38] as reported
previously in the RSV-GENE study [39].
Sample collection and marker detection
Sample collection and processing has been described
previously [40] (and Schuurhof, et al, submitted). Undi-
luted NPAs of infants participating in the RSV-NPA
study were aspirated within 24 hours after admission
and stored at -80°C immediately. Subsequently, the
NPAs were weighed, diluted, sonicated, and centrifuged.
From 200 infants participating in the RSV-NPA study
an adequate volume of NPA was available to measure
the concentration of IL-10 using a commercial ELISA
kit according to the manufacturer’s instructions
(Sanquin Reagents, Amsterdam, The Netherlands).
DNA isolation and genotyping
In all infants participating in the RSV-NPA study buccal
swabs were collected. DNA was isolated from buccal
swabs using the QIAamp Blood Mini Kit (QIAgen,
Venlo, The Netherlands). The DNA concentration was
measured using the NanoDrop (Thermo Scientific,
Breda, The Netherlands). SNP -592C/A, rs1800872 in
IL10 was genotyped using a pre-designed Taqman SNP
genotyping assay (C_1747363_10). For each sample 2.5
μl TaqMan Genotyping master mix, 0.25 μlT a q M a n
primer and 20 ng DNA were used in a total volume of
5 μl .T h er e a c t i o nw a sr u no na7 5 0 0R e a lT i m eP C R
system (Applied Biosystems, Nieuwerkerk a/d IJssel, The
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minutes incubation at 95°C, 40 cycles (15 s, 95°C; 1
min, 60°C), 4°C. Genotyping of the infants and controls
participating in the RSV-GENE study was described pre-
viously [39]. Genotyping failed for 2 of the 235 infants
in the RSV-NPA study. SNP rs1800872 was in Hardy-
Weinberg equilibrium.
Statistical analyses
Logarithmic transformation and logistic regression ana-
lysis were used to analyze the relationship between IL-
10 levels and physician diagnosed PBW. Sample sizes
needed to detect a significant difference were calculated.
We used SD estimates from previous studies. With a =
0.05, b = 0.95, s = 400 and IL-10 levels of 1000 and 750
in the 2 groups, a minimum of 67 children were needed
in both groups. Polymorphism rs1800872 was analyzed
for association with severe RSV disease, physician diag-
nosed PBW, and with the level of IL-10 in NPAs of
RSV infected infants. Genetic analyses were performed
with a c
2 distribution of a 2 × 3 table (df =2 ) .O d d s
ratios determined on genotype level were based on com-
paring heterozygote infants (CA) versus major homozy-
gote infants (CC). IL-10 levels among three genotypes
were compared by using logarithmic transformation and
one-way ANOVA testing. All analyses were performed
using SPSS Statistics 18.0 (Chicago, USA). All hypoth-
esis testing was two-sided, with a five percent threshold
for statistical significance.
Results
General characteristics of 235 RSV infected infants
included in the RSV-NPA study are shown in Table 1.
More boys than girls (55.7% and 44.3%, respectively)
were included, the median age at hospitalization was
two months, and 56.2% of the participating infants were
diagnosed with PBW. We found no significant differ-
ences in baseline characteristics between infants with or
without physician diagnosed PBW, or between our
study population and infants for which follow-up data
were lacking (n = 50).
All 235 infants included in the RSV-NPA study are
shown in this table. Physician diagnosed post-bronchio-
litis wheeze (PBW) in the first year after infection was
not known in fifty infants and these infants were left
out of PBW analyses. No statistical significant differ-
ences are present in the general characteristics of the
infants with or without physician diagnosed PBW, or in
the infants missing follow-up data (n = 50).
1Ranges and
percentages are written between parentheses.
2As e m i -
quantitative parental score for atopy was used [41]. One
point was added to score for presence of each atopic
symptom (eczema, hay fever, bronchitis, asthma, and
food allergy) in both parents, with a minimum score of
0 and a maximum score of 10.
In our previous study, ex vivo monocyte IL-10 pro-
duction during the convalescent phase of RSV bronchio-
litis was shown to be higher in infants with PBW
compared to infants without PBW [32]. To study
whether this difference in IL-10 production is also seen
in the local immune response, levels of IL-10 were ana-
lyzed in NPAs of RSV infected infants with and without
physician diagnosed PBW in the first year after infec-
tion. NPAs were aspirated within 24 hours after admis-
sion to the hospital. IL-10 levels were higher in the
NPAs of RSV infected infants who turned out to
develop physician diagnosed PBW compared to infants
without PBW in the year after RSV infection (958 vs
692 pg/ml, p = 0.02, see Figure 1).
Previously, a significant association between SNP
rs1800872 in the promoter region of the IL10 gene and
severe RSV infection was found in the RSV-GENE study
comparing 349 infants to 1008 population controls (p =
0.021, odds ratio (OR) 0.75 (95% confidence interval (CI)
0.57 - 0.98)), see Figure 2[39]. Heterozygosity was asso-
ciated with reduced susceptibility to severe RSV infection.
In the current study, a remarkably similar association was
observed between this IL10 SNP and severe RSV infec-
tion comparing 157 Dutch infants of the RSV-NPA study
with population controls (p = 0.056, OR 0.76 (95% CI
0.52 - 1.11)), see Figure 2. This association only reached
borderline statistical significance, probably because this
Table 1 General characteristics of RSV infected infants with and without physician diagnosed PBW after RSV
bronchiolitis
Characteristics Infants with PBW (n = 104)
1 Infants without PBW (n = 81)
1 Infants PBW unknown (n = 50)
1
Mechanically ventilated 12 (11.5%) 7 (8.6%) 3 (6.0%)
Mean length of hospitalization in days 6.1 (1-28) 5.2 (1-20) 5.8 (1-25)
Male gender 58 (55.8%) 41 (50.6%) 32 (64.0%)
Dutch nationality 74 (71.2%) 51 (63.0%) 32 (64.0%)
Median gestational age in weeks 39.9 (27.7-42.9) 39.6 (32.9-42.9) 39.0 (35.9-41.6)
Median age at infection in days 71 (8-375) 62 (10-372) 59 (10-308)
Mean parental atopy score
2 1.8 (0-6) 1.7 (0-6) 2.1 (0-6)
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between local IL-10 levels and physician diagnosed PBW.
To study the relevance on the local immune response
and the possible functional effect of this SNP in the
promoter region of IL10,t h el e v e l so fI L - 1 0w e r e
determined in NPAs of RSV infected infants. No differ-
ence was found in the levels of IL-10 among the three
different IL10 genotypes (p = 0.67, see Figure 3). No
association was observed between the IL10 SNP and
physician diagnosed PBW, in children with the CC, AC,
and AA genotype the incidence of PBW was 54.7%,
58.6%, and 56.3% (not significant), respectively.
Discussion
The main finding of this study is that IL-10 levels in
NPAs at the time of hospitalization for severe RSV
infection were highest in infants who developed physi-
cian diagnosed PBW in the year after infection. These
data indicate that the local immune response in infants
at the time of acute, severe RSV infection differentiates
infants with and without subsequent development of
chronic airway morbidity. High IL-10 levels during
severe RSV infection early in life affect airway morbidity
later in life. If this relationship is causal, inhibition of
IL-10 production during acute infection may alter the
incidence of PBW. Further research is needed to study
this relationship. Our current results are consistent with
our previous finding that the production of IL-10 by
monocytes after RSV infection is higher in patients with
recurrent wheezing in follow-up than patients without
Figure 1 IL-10 levels were higher in the NPAs of RSV infected
infants with physician diagnosed PBW. Levels of IL-10 were
determined in nasopharyngeal aspirates (NPAs) of infants
hospitalized for respiratory syncytial virus (RSV) bronchiolitis and
analyzed after logarithmic transformation in groups with and
without physician diagnosed post-bronchiolitis wheeze (PBW) in the
first years after infection. NPAs were aspirated within 24 hours after
admission to the hospital for RSV infection. Horizontal lines indicate
median for analyzed groups. *Logistic regression analysis.
Figure 2 Heterozygosity of IL10 promoter SNP rs1800872 is
negatively associated with risk of severe RSV bronchiolitis.
Each line represents a different cohort, respectively the Dutch
infants of the RSV-NPA study (n = 157), and the Dutch infants of the
RSV-GENE study (n = 349) [39]. RSV infected infants in both cohorts
were compared to the same group of population controls (n =
1008). Odds ratios (OR) and 95% confidence intervals (95% CI) were
determined on genotype level, comparing heterozygote infants (CA)
versus major homozygote infants (CC).
Figure 3 IL-10 levels in NPAs of RSV infected infants did not
differ based on IL10 genotype. Levels of IL-10 were determined
in undiluted nasopharyngeal aspirates (NPAs) of respiratory syncytial
virus (RSV) infected infants and analyzed after logarithmic
transformation. Horizontal lines indicate median for analyzed
groups.
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at the time of RSV infection is the cause of physician
diagnosed PBW or the consequence of a predefined sus-
ceptibility to infection is not yet known. Possibly, infants
with higher IL-10 levels in NPA during acute RSV infec-
tion continue to have high levels of IL-10 during subse-
quent infections and develop more PBW.
Unlike previous publications [21,22,29,30], this is a pro-
spective study which was performed in a large group of
naturally RSV infected infants, all previously healthy and
younger than 13 months of age. Levels of IL-10 at the
time of acute RSV infection were combined with the
development of PBW in infants in the year after RSV
infection. Furthermore, the results of cytokine concentra-
tions and genotyping in infants were compared instead of
detecting mRNA in stimulated cell lines only [42-45].
Following candidate gene identification it is important
to explore the functional consequences of the associated
genetic variation [46]. SNPs located in promoter regions
m a yc h a n g eg e n ee x p r e s s i o nb ya l t e r i n gt r a n s c r i p t i o n
factor binding sites or by other more subtle mechan-
isms. Perrey et al. introduced putative high, intermedi-
ate, and low IL-10 producing haplotypes for three
different IL10 promoter SNPs (rs1800896 (-1082G/A),
rs1800871 (-819C/T), and rs1800872 (-592C/A) which is
in complete linkage disequilibrium with rs1800871) [47].
Many other studies reported associations of these SNPs
with altered transcriptional regulation of IL-10 for vary-
ing diseases [33,48-55]. Heterozygosity of the IL10 SNP
rs1800872 was associated with increased resistance to
severe RSV infection [34,39], suggesting that a balanced
IL-10 response is required to reduce an excessive
immune response, while allowing for a robust anti-viral
immune response. However, no functional effect of this
IL10 SNP on the local immune response could be
detected, i.e. the levels of IL-10 in NPAs were compar-
able among the different genotypes of RSV infected
infants. Whether there is truly no functional conse-
quence of this SNP in the promoter region of IL10 dur-
ing severe RSV infection is not known. We measured
total IL-10 production in NPA irrespective of the source
of IL-10, while there may be a cell type specific effect.
Because protection against severe RSV infection was
associated with heterozygosity of the IL10 SNP, it may
be difficult to observe a functional effect of this promo-
ter SNP. Alternatively, our cohort was too small to
detect subtle differences. Especially the group homozy-
gous for the minor allele consisted only of 17 infants. In
literature, an advantage of the rs1800872 A allele has
been associated to different infectious diseases, however,
a specific heterozygous advantage of the CA genotype is
not mentioned. Replication of this association has not
been published to date. Both Wilson et al. and Helmi-
nen et al. reported no associations between eight SNPs
in IL10 and RSV bronchiolitis [56,57]. However, in a
subgroup analysis, two IL10 SNPs were associated with
the need for mechanical ventilation [56]. In a small
cohort, Gentile et al. showed that more RSV infected
infants with a low IL-10 producing haplotype developed
pneumonia compared to infants with an intermediate or
high IL-10 producing haplotype [58]. Nevertheless,
actual cytokine concentrations were not measured, and
in another study with experimentally RSV challenged
adults no correlation between haplotype and cytokine
levels was observed [58,59]. As we analyzed only the
SNP associated with severe RSV infection instead of
three IL10 promoter SNPs needed to determine the hap-
lotype, we could not compare our data to these studies
[58,59]. Replication of findings from genetic association
studies is required to exclude false positive associations.
It has been difficult to replicate associations with severe
RSV infection due to small sample size in studies, the
related lack of power and the phenotypic heterogeneity
between studies [60,61]. Therefore, more independent
replication studies should be performed to confirm
detected associations.
Conclusion
Higher IL-10 levels in the airways of infants with RSV
infection are observed in infants who subsequently
develop physician diagnosed PBW, emphasizing the
importance of regulation of the local immune response
during RSV bronchiolitis.
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